Bibliographic Details
| Title: |
Durable Remission After Targeted Therapy in BRAF V600E--Mutant Metastatic Colorectal Cancer: Case Report. |
| Authors: |
Fox, Daniel A., Bhamidipati, Deepak, Kopetz, Scott, Hong, David S. |
| Source: |
Journal of Immunotherapy & Precision Oncology; Feb2025, Vol. 8 Issue 1, p11-14, 4p |
| Subject Terms: |
COLORECTAL cancer, BRAF genes, VEMURAFENIB, METASTASIS, DISEASE progression |
| Abstract: |
BRAF mutation leads to constitutive activation of the MAPK pathway and is associated with the immune-activating molecular subtype of colorectal cancer. Targeted therapy for BRAF V600E--mutant metastatic colorectal cancer (CRC) has significantly improved outcomes for these patients when combined with anti--epithelial growth factor receptor (EGFR) therapy. However, most patients ultimately develop disease progression. We report a case of a patient with metastatic-deficient mismatch repair, BRAF V600E--mutated CRC, who achieved a durable complete response to vemurafenib plus cetuximab and chemotherapy despite initial high burden of disease, including peritoneal involvement. Recent clinical trials of combined anti-EGFR/anti--BRAF V600E therapy in BRAF V600E-mutant CRCs have found a few instances of robust response. Further study of combined targeted and chemotherapeutic regimens and the immunogenic properties of BRAF mutation may yield promising results. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Immunotherapy & Precision Oncology is the property of Innovations Journals and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
